Overview
Endothelin Receptor Basic Research Pack (#ESB-940) contains all you need for Endothelin Receptor research: Antibodies for each receptor and selective pharmacological tools, all in one budget friendly package!
Compounds
| Product Name | Cat # | Size |
|---|---|---|
| Antibodies | ||
Anti-Endothelin Receptor A Antibody |
AER-001 | 1 x 0.2 ml |
Endothelin Receptor A Blocking Peptide |
BLP-ER001 | 1 x 40 µg |
Anti-Endothelin Receptor B Antibody |
AER-002 | 1 x 0.2 ml |
Endothelin Receptor B Blocking Peptide |
BLP-ER002 | 1 x 40 µg |
| Activators/Agonists | ||
BQ-3020 |
SPE-200 | 1 x 10 mg |
Sarafotoxin S6b |
SPE-160 | 1 x 1 mg |
| Blockers/Antagonists | ||
A-192621 |
A-360 | 1 x 10 mg |
ACT-132577 |
A-350 | 1 x 10 mg |
BQ-123 sodium salt |
B-185 | 1 x 10 mg |
BQ788 sodium salt |
B-176 | 1 x 5 mg |
FR 139317 |
F-180 | 1 x 10 mg |
Scientific Background
The endothelin system is comprised of three active peptides, ET-1, 2, and 3, which are considered to be very powerful vasoconstrictive substances. In humans, endothelins mediate their actions via two specific G-Protein Coupled Receptors, ETAR and ETBR. Both ETAR and ETBR are present in heart and in human myocardium at similar levels1,2.
The endothelin receptors differ in their ligand specificity. While ETAR has varying affinities for the endothelin isoforms (ET-1 >ET-2>ET-3), ETBR shows no selective affinity.2,3 Subsequent studies have demonstrated the presence of endothelins in vascular as well as in non-vascular cells and tissues, having multiple biological activities.
- Davenport, A.P. (2002) Pharmacol. Rev. 54, 219.
- Boivin, B. et al. (2003) J. Biol.Chem. 278, 29153.
- Grant, K. et al. (2003) Br. J. Cancer. 88, 163.
